The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
113078018 11307801 8 F 20160919 20150724 20160929 EXP DE-ROCHE-1495718 ROCHE , PETERSEN J, HERZER K, FERENCI P, GSCHWANTLER M, WEDEMEYER H, BERG T, SPENGLER U, WEILAND O, VAN DER VALK M, ROCKSTROH J, PECK-RADOSAVLJEVIC M, ZHAO Y, JIMENEZ-EXPOSITO M AND ZEUZEM S. DACLATASVIR PLUS SOFOSBUVIR, WITH OR WITHOUT RIBAVIRIN, ACHIEVED HIGH SUSTAINED VIROLOGICAL RESPONSE RATES IN PATIENTS WITH HCV INFECTION AND ADVANCED LIVER DISEASE IN A REAL-WORLD COHORT. GUT 2016 SEP 07;:1-10. 0.00 Y 0.00000 20160929 MD DE DE

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
113078018 11307801 1 PS RIBAVIRIN. RIBAVIRIN 1 Oral 21511
113078018 11307801 2 SS DACLATASVIR. DACLATASVIR 1 Oral 0
113078018 11307801 3 SS SOFOSBUVIR SOFOSBUVIR 1 Oral 0
113078018 11307801 4 C RITONAVIR. RITONAVIR 1 Unknown 0
113078018 11307801 5 C HIV PROTEINASE INHIBITOR 2 Unknown 0
113078018 11307801 6 C EFAVIRENZ EFAVIRENZ 1 Unknown 0
113078018 11307801 7 C NEVIRAPINE. NEVIRAPINE 1 Unknown 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
113078018 11307801 1 Chronic hepatitis C
113078018 11307801 2 Chronic hepatitis C
113078018 11307801 3 Chronic hepatitis C

Outcome of event

Event ID CASEID OUTC COD
113078018 11307801 DE
113078018 11307801 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
113078018 11307801 Abdominal pain
113078018 11307801 Acute kidney injury
113078018 11307801 Anaemia
113078018 11307801 Anal cancer
113078018 11307801 Arthralgia
113078018 11307801 Calculus urinary
113078018 11307801 Circulatory collapse
113078018 11307801 Clostridium difficile colitis
113078018 11307801 Dehydration
113078018 11307801 Diarrhoea
113078018 11307801 Drug withdrawal syndrome
113078018 11307801 Dyspnoea
113078018 11307801 Erysipelas
113078018 11307801 Fatigue
113078018 11307801 Fluid overload
113078018 11307801 Gastrointestinal infection
113078018 11307801 General physical health deterioration
113078018 11307801 Haemorrhoidal haemorrhage
113078018 11307801 Headache
113078018 11307801 Hepatic encephalopathy
113078018 11307801 Hepatic failure
113078018 11307801 Hepatocellular carcinoma
113078018 11307801 Hypersensitivity vasculitis
113078018 11307801 Hypertension
113078018 11307801 Hyponatraemia
113078018 11307801 Infection
113078018 11307801 Lactic acidosis
113078018 11307801 Liver disorder
113078018 11307801 Lymphoedema
113078018 11307801 Multiple organ dysfunction syndrome
113078018 11307801 Myocardial infarction
113078018 11307801 Nausea
113078018 11307801 Neutropenia
113078018 11307801 Pancreatitis acute
113078018 11307801 Pancytopenia
113078018 11307801 Peritonitis bacterial
113078018 11307801 Portal vein thrombosis
113078018 11307801 Soft tissue infection
113078018 11307801 Somnolence
113078018 11307801 Streptococcal sepsis
113078018 11307801 Vertigo

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

no results found